Sage shakes up leadership, appoints ex AZ and Shire staff
This article was originally published in Scrip
Executive Summary
Biopharmaceutical firm Sage Therapeutics, which develops products to treat CNS disorders and orphan diseases, has appointed Dr Jeffery Jonas chief executive officer. He succeeds Kevin Starr who has been interim CEO since the company's founding in 2011. Prior to joining the Cambridge, Massachusetts-based firm Dr Jonas was president of regenerative medicine at Dublin, Ireland-headquartered biopharmaceutical firm Shire.